Conformis, Inc. to Present at the Cowen 40th Annual Health Care Conference
February 21 2020 - 8:52AM
Conformis, Inc. (NASDAQ:CFMS), a medical technology company that
uses its proprietary iFit Image-to-Implant technology platform to
develop, manufacture, and sell joint replacement implants and
instruments that are individually sized and shaped, and which the
company refers to as personalized or individualized, to fit each
patient’s unique anatomy, announced today that management will
present at the Cowen 40th Annual Health Care Conference in Boston.
The presentation is being made on Wednesday, March 4, 2020, from
11:20 a.m. to 11:50 a.m. EST at the Boston Marriott Copley
Place hotel.
About Conformis, Inc.
Conformis is a medical technology company
that uses its proprietary iFit Image-to-Implant technology platform
to develop, manufacture, and sell joint replacement implants and
instruments that are individually sized and shaped, which we refer
to as personalized, individualized, or sometimes as customized, to
fit each patient’s unique anatomy. Conformis offers a broad
line of sterile, personalized knee and hip implants and single-use
instruments delivered to hospitals. In clinical
studies, the Conformis iTotal CR knee replacement system
demonstrated superior clinical outcomes, including better function
and greater patient satisfaction, compared to traditional,
off-the-shelf implants. Conformis owns or exclusively
in-licenses issued patents and pending patent applications that
cover personalized implants and patient-specific instrumentation
for all major joints.
For more information, visit www.conformis.com.
To receive future releases in e-mail alerts, sign up at
ir.conformis.com.
Cautionary Statement Regarding
Forward-Looking Statements
Statements in this press release about our
future expectations, plans and prospects, including statements
about the anticipated timing of our product launches, and our
financial position and results, total revenue, product revenue,
gross margin, operations and growth, as well as other statements
containing the words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would” and similar expressions, constitute forward-looking
statements within the meaning of the safe harbor provisions of The
Private Securities Litigation Reform Act of 1995. We may not
actually achieve the forecasts disclosed in our forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Actual financial results could
differ materially from the projections disclosed in the
forward-looking statements we make as a result of a variety of
risks and uncertainties, including risks related to our estimates
and expectations regarding our revenue, gross margin, expenses,
revenue growth and other results of operations, and the other risks
and uncertainties described in the “Risk Factors” sections of our
public filings with the Securities and Exchange
Commission. In addition, the forward-looking statements
included in this press release represent our views as of the date
hereof. We anticipate that subsequent events and developments
may cause our views to change. However, while we may elect to
update these forward-looking statements at some point in the
future, we specifically disclaim any obligation to do so.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date
hereof.
Contact
Investor Contact:
Investor Relations
ir@conformis.com
(781) 374-5598
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Apr 2023 to Apr 2024